舊版 AI 分級 · 資料日期 2026-06-01。尚未採用新版自動摘要；未經專家評讀，涵蓋範圍以本頁來源為限。了解新版流程
尿石素A Urolithin A × 老化
結論：證據分歧
獨立判讀為薄弱證據（Tier C）。
C 🟠 C 薄弱證據 證據分歧 🚨 high — heavy affiliate marketing in TW community
獨立判讀為薄弱證據（Tier C）。
最高品質的證據——2024 系統性回顧（PMID 39002645，5 RCTs/n=250）——明確結論『evidence insufficient to confirm meaningful human geroprotective activity』，雖見抗發炎、mitophagy 基因上調與肌力/肌耐力小幅改善，但 ATP 生成、粒線體生物合成/動態、體能、心血管均無顯著效果；且大多數正面 narrative review 由 Amazentis 員工撰寫（明確 COI）。
FDA GRAS / EFSA 500 mg/day / TGA / Health Canada NPN 80128555 之監管支持均限於『食品安全性』，非『老化適應症療效核可』，此種 safety vs efficacy 落差極易被消費者誤讀。
AFAR/AGS/GSA 等老化專業學會無任何 UA 抗老化官方立場或指引，僅 GSA 旗下 Innovation in Aging 收錄產業贊助的會議摘要。
⚖️
評分透明度
所有分數由 7 層證據引擎計算，過程公開可查原始分數 0.58
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
C · 證據分歧
信心度
59%
證據方向分歧
證據層級
E6
多篇較小型隨機對照試驗
▸查看完整決策路徑（audit trail）
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.58
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 0 negative)
- tier_strict_requirement_check — | B→C 因 scope.conflation_risk=true 且 L11 獨評較低 (B7-2 tier cap)
- detect_disputes — 偵測到 1 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
Targeting aging with urolithin A in humans: A systematic review
結論：Dose-dependent anti-inflammatory effect; upregulated mitochondrial/autophagy/FAO genes; increased muscle strength and endurance; NO effect on ATP production, mitochondrial biogenesis/dynamics, microbiota, anthropometrics, cardiovascular outcomes, or physical function; authors conclude evidence insufficient to confirm meaningful geroprotective activity in humans
前往 PubMed Urolithin A as a Potential Agent for Prevention of Age-Related Disease: A Scoping Review
結論：Concludes UA holds potential as dietary intervention for slowing aging and preventing age-related disease via mitophagy and reduced inflammation; evidence remains largely mechanistic/early-clinical
前往 PubMed Mitophagy Activation by Urolithin A to Target Muscle Aging
結論：UA promotes mitophagy, mitochondrial function and improved muscle function across species, multiple experimental models, and several clinical studies; no quantitative pooling reported
前往 PubMed Urolithin A modulates inter-organellar communication via calcium-dependent mitophagy to promote healthy ageing
結論：UA triggers ER Ca2+ release, enhances lysosomal activity and mitophagy; EGTA chelation abolishes lifespan benefit; activates UNC-43/CAMK2D and SKN-1/Nrf2 pathways; in mammalian cells mitigates stress-induced senescence (preclinical mechanism, not human outcomes)
前往 PubMed L4a US FDA
支持
FDA has no questions 來源↗
L4b EU EFSA
中性
In 2022, the European Food Safety Authority (EFSA) gave a positive opinion on the safety of Urolithin A for use in food supplements for the general adult population. The EFSA report emphasized no adverse effects under the proposed daily dose of up to 500 mg/day. 來源↗
L4c UK NHS
未表態
Application for the approval of Urolithin A as a novel food. Applicant: Amazentis SA. Status: In progress. Current Phase: Risk assessment In progress. [ACNFP 173rd meeting, 24-25 Sept 2025] The applicant proposes urolithin A in conventional foods, cereal bars, protein bars, nutrition bars targeting athletes, yoghurt products, specialised foods for adults only, including meal replacements, nutri… 來源↗
L4d TW TFDA / 衛福部
未表態
— 本適應症無對應資料
L4e WHO
支持
Urolithin A is a synthetic version of urolithin A of the compound formed endogenously following consumption of ellagic acid and ellagitannins. Urolithin A is manufactured via chemical synthesis involving a chemical reaction between 2-bromo-5-hydroxybenzoic acid and resorcinol in the presence of sodium hydroxide and catalyst of cupric sulfate pentahydrate, followed by protonation of the resultin… 來源↗
L5a NIH Office of Dietary Supplements
未表態
— 本適應症無對應資料
L5b Mayo Clinic
未表態
— 本適應症無對應資料
L5c Cleveland Clinic
未表態
— 本適應症無對應資料
L5d Harvard Health
未表態
— 本適應症無對應資料
L5e Specialty Society (condition-mapped)
中性
UA is well tolerated and has an attractive safety profile when orally administered in single and multiple doses to elderly. 來源↗
PTT · Dcard · Mobile01 彙整自公開論壇討論，非統計抽樣，僅反映社群風向。
廣告 / 業配密度 極高
低中高
📍立場總覽
尿石素A（Urolithin A）用於抗老在台灣 PTT/Dcard/Mobile01 幾乎沒有真實鄉民實測討論。PTT 抗老相關文多為 A醇、胜肽、早C晚A 等保養話題，與尿石素A無關。現有中文資訊集中在 IQ健康網、康健、大紀元、GeneOnline 等商業健康媒體與 Mitopure/原料供應商行銷頁，屬高度業配污染來源，無法反映在地真實使用經驗。研判此為冷門新興原料，社群討論量不足，無法萃取有效在地經驗。
💬社群實感
無共識：台灣 PTT/Dcard/Mobile01 缺乏實際使用心得，無法判定鄉民實測效果。
- 規律身體活動（有氧、肌力與平衡訓練）
- 戒菸
查看 ClaimReview 結構化資料 (JSON-LD)
{
"@context": "https://schema.org",
"@type": "ClaimReview",
"url": "https://gpt-dict.com/claim/CLM-COND-aging-INT-urolithin-a-001/",
"datePublished": "2026-06-01",
"author": {
"@type": "Organization",
"name": "gpt-dict.com",
"url": "https://gpt-dict.com"
},
"claimReviewed": "尿石素A能改善老化",
"inLanguage": "zh-TW",
"itemReviewed": {
"@type": "Claim",
"appearance": []
},
"reviewRating": {
"@type": "Rating",
"ratingValue": 2,
"bestRating": 5,
"worstRating": 1,
"alternateName": "🟠 C 薄弱證據"
}
}